In metabolic therapy, the amygdalin is broken down into its component parts as a result of the action of the betaglucidase. This enzyme is found in abundance in cancer cells, and is relatively deficient in normal cells.
Consequently, the cyanide is released only where there is an active cancer lesion. This liberation of cyanide under controlled and safe conditions insures that an adequate dosage can be administered without the threat of toxic side effects.
This
absence of cyanide toxicity is further insured by the action of the
thodanese, another enzyme. This enzyme is present in large quantities
in normal cells but in very small amounts in cancer cells.
Detoxification of cyanide occurs, therefore, in normal mammalian tissue through the action of this rhodanese which, in the presence of sulfer-bearing compounds, converts free cyanide to thiocyanate, a perfectly nontoxic compound. The thiocynate is excreted in the urine.
Administration of Amygdalin
Slow drip infusion. The most efficacious mode of administration is through the slow-drip infusion technique which was developed in Tijuana, Mexico. It became apparent that the breakdown of amygdalin and its subsequent detoxification was very rapid.
If
it were to be administered over a longer period of time, this could
be overcome. In addition, the amygdalin must pass through many biological
membranes in order to reach its site of action. This can be accomplished
by combining the amygdalin with Dimethylsulfoxide (DMSO-laboratory
grade).
Finally, as vitamin C is known to slow the growth of tumors, it is added to allow the amygdalin and the rest of the metabolic therapy more time to work.
The amygdalin should be added just prior to injection to insure maximum potency. This complete infusion is administered intravenously over a 2 to 3 hour period.
More rapid administration can result in a localized burning sensation due to the large amounts of vitamin C. This infusion is administered daily over the first 21 days of metabolic therapy.
Intravenous Injection:
In
some instances where the slow drip infusion is not practical, intravenous
administration of amygdalin can be used. This method provides the
same high concentration in the blood as the slow drip infusion. Three vials (3 grams each) are administered daily in a slow intravenous
push, usually in the brachial vein just proximate to the elbow. Preferably
this administration should be between meals. The intravenous administration
should be daily for 21 days.
Oral Ingestion:
This
is the most convenient and most frequently used method of amygdalin
administration. The patients leaving the clinic are placed on oral
amygdalin. Also, because of the difficulty for some patients in going
to the physician's daily, many doctors prefer this method.
For
Treatment:
The
tablet size is 500 milligrams (mg). Two of these tablets should be
given 3 times a day. If patients have difficulty swallowing, the
tablets may be broken up and added to soft food. The patient should
take 1 tablet six times a day.
As
A Preventive:
The tablet size is 100mg. One or two tablets should be taken daily. This data is provided for informational purposes only by Cyto Pharma of Mexico. This company has been in the market since 1971 and are well known worldwide. They are the leader in the field of the amygdalin process and their research staff is constantly working to upgrade their products.
